Free Trial
→ Missed the Run So Far? This Is Your Second Chance (From Crypto Swap Profits) (Ad)
LON:SCLP

Scancell 1/30/2025 Earnings Report

Scancell logo
GBX 10.22 -0.13 (-1.21%)
As of 07/18/2025 11:23 AM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 1.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Date
1/30/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Scancell Hldgs Plc (SCLP)
February 21, 2025  |  uk.investing.comhttps://uk.investing.com/equities/scancell-holdings-plc
Scancell Holdings Grants Share Options to Executive Directors
February 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scancell-holdings-grants-share-options-to-executive-directors?utm_source=marketbeat.com&utm_medium=referral
Altucher: Turn $900 into $108,000 in just 12 months?
Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.
July 20 at 2:00 AM  |  Paradigm Press (Ad)
With 42% stake, Scancell Holdings plc (LON:SCLP) seems to have captured hedge funds investors' interest
January 19, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/42-stake-scancell-holdings-plc-074026965.html
Scancell Holdings Secures £11.3 Million in Oversubscribed Offering
December 9, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scancell-holdings-secures-11-3-million-in-oversubscribed-offering-1034114022
Scancell Holdings Shows Promising Results in SCOPE Trial
November 18, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/scancell-holdings-shows-promising-results-in-scope-trial/ar-AA1uhvfn
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

View Scancell Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles